Media stories about Applied Genetic Technologies (NASDAQ:AGTC) have trended somewhat positive recently, Accern reports. The research group identifies positive and negative press coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Applied Genetic Technologies earned a coverage optimism score of 0.02 on Accern’s scale. Accern also gave news coverage about the biotechnology company an impact score of 43.8020445065046 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

A number of research analysts have recently issued reports on the stock. HC Wainwright restated a “buy” rating and issued a $8.00 price target on shares of Applied Genetic Technologies in a research report on Wednesday, November 8th. Zacks Investment Research downgraded shares of Applied Genetic Technologies from a “hold” rating to a “sell” rating in a research report on Tuesday, January 9th. Cantor Fitzgerald set a $9.00 target price on shares of Applied Genetic Technologies and gave the company a “hold” rating in a research report on Friday, October 6th. ValuEngine downgraded shares of Applied Genetic Technologies from a “sell” rating to a “strong sell” rating in a research report on Sunday, December 31st. Finally, Wedbush reiterated an “outperform” rating and set a $9.00 target price on shares of Applied Genetic Technologies in a research report on Wednesday, November 8th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company. The company has an average rating of “Hold” and an average price target of $10.17.

Applied Genetic Technologies (NASDAQ:AGTC) traded up $0.05 during trading on Friday, hitting $4.00. 51,900 shares of the company were exchanged, compared to its average volume of 107,517. Applied Genetic Technologies has a 52 week low of $3.25 and a 52 week high of $9.45. The firm has a market cap of $71.47, a P/E ratio of -20.00 and a beta of 1.62.

Applied Genetic Technologies (NASDAQ:AGTC) last released its earnings results on Tuesday, November 7th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.14) by $0.06. Applied Genetic Technologies had a negative net margin of 8.78% and a negative return on equity of 2.86%. analysts predict that Applied Genetic Technologies will post -1.14 EPS for the current year.

COPYRIGHT VIOLATION WARNING: “Applied Genetic Technologies (AGTC) Receives Media Impact Rating of 0.02” was first published by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another website, it was illegally copied and reposted in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://www.watchlistnews.com/applied-genetic-technologies-agtc-receives-media-impact-rating-of-0-02/1813996.html.

About Applied Genetic Technologies

Applied Genetic Technologies Corporation is a clinical-stage biotechnology company. The Company develops gene therapy products designed to manage the lives of patients with severe diseases in ophthalmology. As of March 31, 2016, its product candidates included treatments for X-linked retinoschisis (XLRS), over two forms of achromatopsia (ACHM) and X-linked retinitis pigmentosa (XLRP).

Insider Buying and Selling by Quarter for Applied Genetic Technologies (NASDAQ:AGTC)

Receive News & Ratings for Applied Genetic Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Applied Genetic Technologies and related companies with MarketBeat.com's FREE daily email newsletter.